Targets such as HRD, BRAF, RET, HER2, and PD‐1/PD‐L1 have also emerged on the stage [5, 6], but seldom research indicates that ALK inhibitors may be effective in the treatment of EML4‐ALK+ ovarian cancer [7]. This evidence concerns the gene ALK and ovarian carcinoma.